NZ795266A - Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety - Google Patents

Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety

Info

Publication number
NZ795266A
NZ795266A NZ795266A NZ79526621A NZ795266A NZ 795266 A NZ795266 A NZ 795266A NZ 795266 A NZ795266 A NZ 795266A NZ 79526621 A NZ79526621 A NZ 79526621A NZ 795266 A NZ795266 A NZ 795266A
Authority
NZ
New Zealand
Prior art keywords
formula
compound
salt
halogen
independently hydrogen
Prior art date
Application number
NZ795266A
Other versions
NZ795266B2 (en
Inventor
Haiming Zhang
Jie Xu
Georg Wuitschik
Remy Angelaud
Sebastian Herold
Alfred Stutz
Tobias Bruetsch
Johannes Burkhard
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of NZ795266A publication Critical patent/NZ795266A/en
Publication of NZ795266B2 publication Critical patent/NZ795266B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/10—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms two oxygen atoms and one sulfur atom, e.g. cyclic sulfates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)

Abstract

Provided herein are processes for the preparation of intermediate compounds of formula (II) and of compounds of formula (I) which are useful in the treatment of cancer.

Claims (28)

CLAIM
1. A process for the preparation of a compound of formula (II): or a stereoisomer or salt thereof 1a 1b each of R and R is independently hydrogen, halogen, unsubstituted C1-3 alkyl, unsubstituted C1-3 haloalkyl, or unsubstituted C1-3 alkoxy; each R is independently halogen, hydroxyl, -CN, unsubstituted C alkyl, unsubstituted C1-3 haloalkyl, or unsubstituted C1-3 alkoxy; m is 0, 1 or 2; and n is 1, 2, or 3; the process comprising: (a) contacting a compound of formula (III), (III) or a stereoisomer or salt thereof with an acid selected from H2SO4 and ClSO3H to form a compound of formula (IIIa); (IIIa) or a stereoisomer or salt thereof (b) contacting the compound of formula (IIIa) of step (a) or a stereoisomer or salt thereof with a base to form compound of formula (IV); or a stereoisomer or salt thereof (c) hydrogenating the compound of formula (IV) of step (b) or a stereoisomer or salt thereof, in the presence of a catalyst to form a compound of formula (V); and or a stereoisomer or salt thereof (d) contacting the compound of formula (V) of step (c) or a stereoisomer or salt thereof with a compound of formula (VI); thereby forming a compound of formula (II) or a stereoisomer or salt thereof.
2. The process of claim 1, wherein the compound of formula (III) is a compound of formula (III*) (III*).
3. The process of claim 2, wherein the compound of formula (III*) is a compound of formula (3*), (3x*), (3y*), or (3z*) (3*), (3x*), (3y*), or (3z*).
4. The process of claim 2, wherein the compound of formula (III*) is a compound of formula (3*) (3*).
5. The process of any one of claims 1-4, wherein the acid is ClSO H.
6. The process of any one of claims 1-5, wherein the base is a hydroxide base selected from KOH, NaOH, or LiOH.
7. The process of any one of claims 1-6, wherein the catalyst comprises Pd, Pt, or Ni.
8. The process of claim 7, wherein the catalyst is Pd/C, Pt/C, or Raney Ni.
9. The process of any one of claims 1-8, wherein the hydrogenation is performed in the presence of isopropanol, formic acid, formate, or ammonium.
10. The process of any one of claims 1-9, wherein the compound of formula (VI) is: , , , , , , or , including stereoisomers thereof. 1a 1b
11. The process of any one of claims 1-10, wherein each R and each R is independently hydrogen, halogen, or methyl.
12. The process of any one of claims 1-10, wherein each R is hydrogen and each R is independently hydrogen, halogen, or methyl.
13. The process of any one of claims 1-10, wherein each R is hydrogen and each R is independently hydrogen or halogen.
14. The process of any one of claims 1-10, wherein each R is hydrogen and each R is independently hydrogen or methyl.
15. The process of any one of claims 1-10, wherein each R is independently hydrogen or methyl and each R is independently hydrogen, halogen, or methyl.
16. The process of any one of claims 1-10, wherein each R is independently hydrogen or halogen and each R is independently hydrogen, halogen, or methyl.
17. The process of any one of claims 1-10, wherein each R is independently hydrogen or halogen and each R is independently hydrogen or halogen. 1a 1b
18. The process of any one of claims 1-10, wherein each R and each R are independently hydrogen or F.
19. The process of any one of claims 1-18, wherein each R is independently hydrogen, halogen, hydroxyl, -CN, or unsubstituted C alkyl.
20. The process of any one of claims 1-19, wherein m is 0.
21. The process of any one of claims 1-19, wherein m is 1.
22. The process of any one of claims 1-19, wherein R is halogen and m is
23. The process of any one of claims 1-22, wherein the compound of formula (II) is: , , , or , , or a stereoisomer or salt thereof.
24. The process of any one of claims 1-20, wherein the compound of formula (II) is: or a salt thereof.
25. The process of any one of claims 1-24, wherein the compound of formula (II) is contacted with a compound having formula (X): or a stereoisomer or salt thereof ring A is phenyl or pyridinyl; each R is independently hydrogen, halogen, or C alkyl, R is halogen or -CN; and p is 1 or 2; to form a compound of formula (I): or a stereoisomer or pharmaceutically acceptable salt thereof.
26. The process of claim 25, wherein the compound of formula (X) is: , , , H C CH , , , , , , , , , , , , , , , , , , or , or a salt thereof.
27. A process for the synthesis of a compound having the formula (1), the process comprising: or a pharmaceutically acceptable salt thereof. (a) contacting a compound of formula (2) or a salt thereof wherein the compound of formula (2) is synthesized according to the process of claim 1and wherein the compound of formula (V) has formula (5) or a salt thereof and the compound of formula (VI) has formula (6): (b) with a compound of formula (10); or a salt thereof thereby making a compound of formula (1) or a pharmaceutically acceptable salt thereof.
28. The process of any one of claims 1-27 substantially as herein described and with reference to any example thereof.
NZ795266A 2021-06-28 Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety NZ795266B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063046216P 2020-06-30 2020-06-30
PCT/US2021/039325 WO2022005943A2 (en) 2020-06-30 2021-06-28 Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety

Publications (2)

Publication Number Publication Date
NZ795266A true NZ795266A (en) 2025-11-28
NZ795266B2 NZ795266B2 (en) 2026-03-03

Family

ID=

Also Published As

Publication number Publication date
US11873305B2 (en) 2024-01-16
TWI861689B (en) 2024-11-11
JP2024056684A (en) 2024-04-23
PE20230853A1 (en) 2023-05-29
WO2022005943A3 (en) 2022-02-17
CL2024002477A1 (en) 2025-01-03
IL299388A (en) 2023-02-01
CN115916750A (en) 2023-04-04
CR20230048A (en) 2023-03-20
IL325189A (en) 2026-02-01
BR112022026981A2 (en) 2023-01-24
US12448386B2 (en) 2025-10-21
TW202208363A (en) 2022-03-01
US20250388590A1 (en) 2025-12-25
JP7857978B2 (en) 2026-05-13
US20220002304A1 (en) 2022-01-06
CN120623091A (en) 2025-09-12
EP4172144A2 (en) 2023-05-03
AR122781A1 (en) 2022-10-05
CL2022003810A1 (en) 2023-06-02
KR20250171413A (en) 2025-12-08
JP7419503B2 (en) 2024-01-22
TW202334149A (en) 2023-09-01
TWI794856B (en) 2023-03-01
US20240174678A1 (en) 2024-05-30
KR20230031321A (en) 2023-03-07
MX2022015880A (en) 2023-02-27
IL299388B2 (en) 2026-08-01
KR102890015B1 (en) 2025-11-25
AU2021299200A1 (en) 2023-02-23
JP2023500557A (en) 2023-01-10
UA130123C2 (en) 2025-11-19
CA3188350A1 (en) 2022-01-06
IL299388B1 (en) 2026-04-01
WO2022005943A2 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
MX2022015880A (en) Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety.
ZA202110422B (en) Heterocyclic compounds, preparation methods and uses thereof
IL316706A (en) Macrocycle compounds for the treatment of cancer
AU2024220916A1 (en) Tricyclic compounds for the treatment of cancer
ES3065771T3 (en) Substituted oxoisoindoline compounds for the treatment of cancer
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
PL1853602T3 (en) Chemical compounds
SI1853588T1 (en) Chemical compounds
MX2020011907A (en) Kras g12c inhibitors for the treatment of cancer.
CY1121885T1 (en) ANTI-TUMOR COMPOUNDS
TW200605886A (en) Indazoles useful in treating cardiovascular diseases
EP2298304A3 (en) Carboline derivatives useful in the treatment of cancer
MX2007002398A (en) New pharmaceutical compositions for the treatment of cancer.
UA95298C2 (en) Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumor agents
CR20230382A (en) Bicyclic tetrahydroazepine derivatives for the treatment of cancer
TNSN08020A1 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
IL307338A (en) Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
MX2025001982A (en) Inhibitors of kif18a and uses thereof
EA200601884A1 (en) BETA CARBOLINS USED FOR THE TREATMENT OF INFLAMMATORY DISEASES
NZ779815A (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
MY141233A (en) Enantiomers of selected fused heterocyclics and uses thereof
BR0116123A (en) Antitumor Carbazoles
MX2007001954A (en) Selected fused heterocyclics and uses thereof.
CA3283535A1 (en) Tricyclic compounds for the treatment of cancer
CA3308038A1 (en) Compositions for the treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed